cadisegliatin Updated Nov 8
The next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.
- Cadisegliatin has FDA Breakthrough Therapy designation (May 2026) and Orphan Drug Designation (October 2026), signaling regulatory interest and potential for accelerated development and priority review.
- Phase 2 SimpliciT-1 data showed HbA1c improvement and fewer severe hypoglycemia events, a compelling profile for an oral adjunctive therapy in T1D where no oral adjunctive options currently exist.
- Analyst consensus is strongly bullish: 12 analysts rate it Buy/Strong Buy with a mean price target of $56, implying 166% upside from the current ~$21 stock price near its 52-week low.
- Phase 3 CATT1 topline results are not expected until mid 2027, leaving a long period with no binary catalyst during which the stock could drift or face dilution.
- The company reported a Q3 2026 net loss of $11.62 million, and with no approved products generating revenue, vTv will likely need to raise capital, causing shareholder dilution.
- The drug was placed on clinical hold by the FDA in July 2024 (lifted March 2025), indicating regulatory risk and potential for future holds if safety signals emerge.